CVS Health analysis indicates GLP-1 drugs (Eli Lilly, Novo Nordisk) are only cost-effective for health plans if priced under $350/month. Current prices, often $617-$766/month for employers, add to overall spending despite reduced medical service use. This analysis suggests significant pressure on drugmakers to lower prices, as 14% of companies plan to drop GLP-1 obesity coverage in 2027 due to high costs.
CVS says GLP-1s save money when priced below $350 per month
INVESTING.COMNov 14, 11:06 AM UTC
0